Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities.

Oz S, Ivashko-Pachima Y, Gozes I.

PLoS One. 2012;7(12):e51458. doi: 10.1371/journal.pone.0051458. Epub 2012 Dec 14.

2.

Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.

Shiryaev N, Pikman R, Giladi E, Gozes I.

Curr Pharm Des. 2011;17(25):2603-12. Review.

PMID:
21728979
3.

Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).

Gozes I.

Curr Pharm Des. 2011;17(31):3413-7. Review.

PMID:
21902667
4.

ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy.

Ivashko-Pachima Y, Sayas CL, Malishkevich A, Gozes I.

Mol Psychiatry. 2017 Sep;22(9):1335-1344. doi: 10.1038/mp.2016.255. Epub 2017 Jan 24.

PMID:
28115743
5.

Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide).

Gozes I, Iram T, Maryanovsky E, Arviv C, Rozenberg L, Schirer Y, Giladi E, Furman-Assaf S.

J Alzheimers Dis. 2014;40 Suppl 1:S23-36. doi: 10.3233/JAD-131664.

PMID:
24503616
6.

The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins.

Oz S, Kapitansky O, Ivashco-Pachima Y, Malishkevich A, Giladi E, Skalka N, Rosin-Arbesfeld R, Mittelman L, Segev O, Hirsch JA, Gozes I.

Mol Psychiatry. 2014 Oct;19(10):1115-24. doi: 10.1038/mp.2014.97. Epub 2014 Sep 2.

PMID:
25178163
7.

Peptide neuroprotection through specific interaction with brain tubulin.

Divinski I, Holtser-Cochav M, Vulih-Schultzman I, Steingart RA, Gozes I.

J Neurochem. 2006 Aug;98(3):973-84.

8.

The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection.

Gozes I, Divinski I.

J Alzheimers Dis. 2004 Dec;6(6 Suppl):S37-41.

PMID:
15665412
9.

NAP alpha-aminoisobutyric acid (IsoNAP).

Gozes I, Schirer Y, Idan-Feldman A, David M, Furman-Assaf S.

J Mol Neurosci. 2014 Jan;52(1):1-9. doi: 10.1007/s12031-013-0103-8.

PMID:
24458740
10.

NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42).

Gozes I, Divinski I, Piltzer I.

BMC Neurosci. 2008 Dec 10;9 Suppl 3:S3. doi: 10.1186/1471-2202-9-S3-S3.

12.

D-SAL and NAP: Two Peptides Sharing a SIP Domain.

Gozes I, Sragovich S, Schirer Y, Idan-Feldman A.

J Mol Neurosci. 2016 Jun;59(2):220-31. doi: 10.1007/s12031-015-0701-8.

PMID:
26816081
13.

Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP).

Magen I, Gozes I.

Neuropeptides. 2013 Dec;47(6):489-95. doi: 10.1016/j.npep.2013.10.011. Epub 2013 Oct 24. Review.

PMID:
24210139
14.

From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division.

Gozes I, Divinsky I, Pilzer I, Fridkin M, Brenneman DE, Spier AD.

J Mol Neurosci. 2003;20(3):315-22. Review.

PMID:
14501014
15.

Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.

Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, Gozes I.

J Pharmacol Exp Ther. 2007 Nov;323(2):438-49. Epub 2007 Aug 24.

16.

Nerve growth factor induces neurite outgrowth of PC12 cells by promoting Gβγ-microtubule interaction.

Sierra-Fonseca JA, Najera O, Martinez-Jurado J, Walker EM, Varela-Ramirez A, Khan AM, Miranda M, Lamango NS, Roychowdhury S.

BMC Neurosci. 2014 Dec 31;15:132. doi: 10.1186/s12868-014-0132-4.

18.

NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport.

Jouroukhin Y, Ostritsky R, Assaf Y, Pelled G, Giladi E, Gozes I.

Neurobiol Dis. 2013 Aug;56:79-94. doi: 10.1016/j.nbd.2013.04.012. Epub 2013 Apr 28.

PMID:
23631872
19.

NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).

Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L.

CNS Drug Rev. 2005 Winter;11(4):353-68. Review.

20.

Supplemental Content

Support Center